When is Wegovy typically denied?
Wegovy is Novo Nordisk's semaglutide 2.4 mg formulation indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight with comorbidities, and cardiovascular risk reduction in adults with established CVD and overweight or obesity. Insurance denials are common — particularly for plans that restrict GLP-1s to specific diagnoses or require step therapy. Knowing the exact denial reason on your Explanation of Benefits (EOB) is the first step toward a successful appeal.
Common denial reasons & how to counter them
Plan excludes weight-loss medications
If your plan excludes anti-obesity drugs entirely, pivot to the cardiovascular indication — Wegovy is approved to reduce major adverse cardiovascular events in adults with established CVD and overweight or obesity.
BMI below plan threshold
Document BMI from the most recent clinic visit and include comorbidities (T2D, HTN, dyslipidemia, OSA). Many plans accept BMI ≥ 27 with at least one comorbidity.
Step therapy not completed
Submit documentation of prior trials — phentermine, orlistat, structured lifestyle programs — with dates and outcomes. If contraindicated, document why.
Diagnosis code mismatch
Confirm the prescriber used a covered ICD-10 (E66.01 morbid obesity, E66.9 obesity, Z68.xx BMI codes) plus comorbidity codes. Resubmit with the correct codes if needed.
Documentation checklist
Strong appeals are built on documentation. Ask your prescriber's office to include each of the following in the appeal packet:
- Most recent BMI with date of measurement
- ICD-10 codes for obesity and all weight-related comorbidities
- Prior weight-management therapies tried, with dates and outcomes
- Chart notes from at least two clinic visits documenting weight history
- Letter of medical necessity from the prescriber
- Relevant labs (A1c, lipid panel, liver function)
- Copy of the original denial letter / EOB
Sample appeal letter for Wegovy
Copy the letter below into your appeal and have your prescriber personalize the clinical details. Always attach supporting chart notes and lab results.
[Date] [Insurance Plan Name] Attn: Appeals Department [Address] Re: Appeal of Denial — Wegovy (semaglutide 2.4 mg) Member: [Patient Name] Member ID: [ID] Claim/Reference #: [from denial letter] To the Appeals Reviewer: I am writing to formally appeal the denial of coverage for Wegovy (semaglutide 2.4 mg) issued on [denial date]. The stated denial reason was: "[exact reason from EOB]." [Patient Name] is a [age]-year-old [sex] with a BMI of [BMI] and the following weight-related comorbidities: [list — e.g., type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, established cardiovascular disease]. Wegovy is FDA-approved for chronic weight management in adults with a BMI ≥ 30, or ≥ 27 with at least one weight-related comorbidity, and for cardiovascular risk reduction in adults with established CVD and overweight or obesity. [Patient] meets the labeled indication based on the clinical documentation enclosed. [Patient] has previously attempted lifestyle modification (documented in chart notes dated [dates]) and trials of [list prior therapies — e.g., phentermine, orlistat] without sustained clinical response. Continued obesity in this patient carries significant medical risk, and Wegovy represents the most evidence-supported next step. Enclosed please find: (1) chart notes documenting BMI and comorbidities, (2) records of prior weight-management interventions, (3) the prescriber's letter of medical necessity, and (4) relevant lab results. I respectfully request that this denial be overturned and Wegovy be approved. Sincerely, [Prescriber Name, Credentials] [Practice / NPI]
FAQ
Get a Wegovy approval-likelihood score
Answer a few clinical questions and receive a personalized assessment of your approval odds, plus a prior-authorization checklist tailored to your plan.
Educational guidance only — not medical or legal advice.